Cargando…

PAX2 Expression in Low Malignant Potential Ovarian Tumors and Low-Grade Ovarian Serous Carcinomas

Ovarian tumors of low-malignant potential and low-grade ovarian serous carcinomas are thought to represent different stages on a tumorigenic continuum and to develop along pathways distinct from high-grade ovarian serous carcinoma. We performed gene expression profiling on 3 normal human ovarian sur...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tung, Celestine S., Mok, Samuel C., Tsang, Yvonne T.M., Zu, Zhifei, Song, Huijuan, Liu, Jinsong, Deavers, Michael, Malpica, Anais, Wolf, Judith K., Lu, Karen H., Gershenson, David M., Wong, Kwong-Kwok
Formato:	Texto
Lenguaje:	English
Publicado:	2009
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2736318/ https://www.ncbi.nlm.nih.gov/pubmed/19525924 http://dx.doi.org/10.1038/modpathol.2009.92

Ejemplares similares

PAX2 Expression in Ovarian Cancer
por: Song, Huijuan, et al.
Publicado: (2013)

The Continuum of Serous Tumors of Low Malignant Potential and Low-Grade Serous Carcinomas of the Ovary
por: Wong, Kwong-Kwok, et al.
Publicado: (2007)

Integrated multi-omic analysis of low-grade ovarian serous carcinoma collected from short and long-term survivors
por: Wong, Kwong-Kwok, et al.
Publicado: (2022)

Intratumoral heterogeneity in a minority of ovarian low-grade serous carcinomas
por: Tone, Alicia A, et al.
Publicado: (2014)

Trends of low-grade serous ovarian carcinoma in the United States
por: Matsuo, Koji, et al.
Publicado: (2018)

Low-grade serous ovarian cancer: expert consensus report on the state of the science
por: Grisham, Rachel N, et al.
Publicado: (2023)

Impact of mutational status on survival in low-grade serous carcinoma of the ovary or peritoneum
por: Gershenson, David M, et al.
Publicado: (2015)

UnPAXing the Divergent Roles of PAX2 and PAX8 in High-Grade Serous Ovarian Cancer
por: Hardy, Laura R., et al.
Publicado: (2018)

Nutlin-3a: A Potential Therapeutic Opportunity for TP53 Wild-Type Ovarian Carcinomas
por: Crane, Erin K., et al.
Publicado: (2015)

Low-grade Serous Ovarian Carcinoma
por: Ricciardi, Enzo, et al.
Publicado: (2018)

Testing for NRAS Mutations in Serous Borderline Ovarian Tumors and Low-Grade Serous Ovarian Carcinomas
por: Sadlecki, Pawel, et al.
Publicado: (2018)

Development of Low-Grade Serous Ovarian Carcinoma from Benign Ovarian Serous Cystadenoma Cells
por: Dey, Puja, et al.
Publicado: (2022)

Concurrent Primary Peritoneal Low-Grade Serous Carcinoma and Endometrial High-Grade Serous Carcinoma
por: Lockyer, Megan G., et al.
Publicado: (2015)

Proteome profiling of low grade serous ovarian cancer
por: zadeh fakhar, Haniyeh Bashi, et al.
Publicado: (2019)

ELF3 is a negative regulator of epithelial-mesenchymal transition in ovarian cancer cells
por: Yeung, Tsz-Lun, et al.
Publicado: (2017)

Peritoneal inflammation – A microenvironment for Epithelial Ovarian Cancer (EOC)
por: Freedman, Ralph S, et al.
Publicado: (2004)

Candidate genes and pathways downstream of PAX8 involved in ovarian high-grade serous carcinoma
por: de Cristofaro, Tiziana, et al.
Publicado: (2016)

Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci
por: Kar, Siddhartha P, et al.
Publicado: (2017)

Morphological and molecular basis of ovarian serous carcinoma
por: Rosen, Daniel G, et al.
Publicado: (2010)

Differences in gynecologic tumor development in Amhr2-Cre mice with KRAS(G12D) or KRAS(G12V) mutations
por: Kun, Eucharist H. S., et al.
Publicado: (2020)

PAX8 lineage-driven T cell engaging antibody for the treatment of high-grade serous ovarian cancer
por: Lee, Emily, et al.
Publicado: (2021)

PAX8 modulates the tumor microenvironment of high grade serous ovarian cancer through changes in the secretome
por: Salvi, Amrita, et al.
Publicado: (2022)

Low-grade serous carcinoma with extensive osseous metaplasia arising from ovarian serous cystadenofibroma
por: Ribeiro e Ribeiro, Renan, et al.
Publicado: (2021)

The Role of GDF15 in Regulating the Canonical Pathways of the Tumor Microenvironment in Wild-Type p53 Ovarian Tumor and Its Response to Chemotherapy
por: Izaguirre, Daisy I., et al.
Publicado: (2020)

Cardiophrenic lymph node metastasis in low-grade serous ovarian adenocarcinoma
por: Serna-Gallegos, Tasha, et al.
Publicado: (2016)

Low Grade Ovarian Serous Carcinoma - A Clinical-Morphologic Study
por: DOCHIȚ, C, et al.
Publicado: (2019)

Low-Grade Ovarian Serous Adenocarcinoma with Lymph Node Metastasis in Neck
por: Chen, Shih-Lung, et al.
Publicado: (2021)

Immunohistochemical profiling of benign, low malignant potential and low grade serous epithelial ovarian tumors
por: Ouellet, Véronique, et al.
Publicado: (2008)

Genome Wide DNA Copy Number Analysis of Serous Type Ovarian Carcinomas Identifies Genetic Markers Predictive of Clinical Outcome
por: Engler, David A., et al.
Publicado: (2012)

TGF-Beta Induces Serous Borderline Ovarian Tumor Cell Invasion by Activating EMT but Triggers Apoptosis in Low-Grade Serous Ovarian Carcinoma Cells
por: Cheng, Jung-Chien, et al.
Publicado: (2012)

Prediction of chemotherapeutic resistance in serous ovarian cancer with low-density custom microarray
por: Zhu, Hong-Lan, et al.
Publicado: (2020)

Skin Metastasis of Low-Grade Ovarian Serous Carcinoma: A Case Report
por: Ching, Lauren M, et al.
Publicado: (2023)

Bevacizumab Treatment for Low-Grade Serous Ovarian Cancer: A Systematic Review
por: Lazurko, Caitlin, et al.
Publicado: (2023)

Loss of PAX8 in high-grade serous ovarian cancer reduces cell survival despite unique modes of action in the fallopian tube and ovarian surface epithelium
por: Rodgers, Laura H., et al.
Publicado: (2016)

The PAX8 cistrome in epithelial ovarian cancer
por: Adler, Emily K., et al.
Publicado: (2017)

A long-term surviving patient with recurrent low-grade serous ovarian carcinoma treated with the MEK1/2 inhibitor, selumetinib
por: Takekuma, Munetaka, et al.
Publicado: (2016)

BRAF(V600E)-mutated ovarian serous borderline tumors are at relatively low risk for progression to serous carcinoma
por: Chui, M. Herman, et al.
Publicado: (2019)

PAX8 expression in high-grade serous ovarian cancer positively regulates attachment to ECM via Integrin β3
por: Soriano, Amata Amy, et al.
Publicado: (2019)

Ovarian low and high grade serous carcinomas: hidden divergent features in the tumor microenvironment
por: Ciucci, Alessandra, et al.
Publicado: (2016)

Loss of 1p36.33 Frequent in Low-Grade Serous Ovarian Cancer
por: Van Nieuwenhuysen, Els, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_q27t1ln26it2bog73h25rdh5rp